×

Biotech and Pharmaceuticals Medicine

  • Feb 10- Drug developer Immunomedics Inc said on Friday it entered into a development and licensing deal worth up to $2 billion for its experimental cancer drug with Seattle Genetics Inc.. The drug is currently in an early stage study in advanced breast cancer patients whose disease has progressed despite multiple therapies, and has won the U.S. Food and Drug...

  • dog veterinarian pet care

    Pet care is now very advanced, and expensive. But veterinary experts say you don’t have to spend a bundle to increase a pet's life span.

  • PBMs are able to negotiate on drug prices: Dave Dorman

    Dave Dorman, CVS Health non-excutive chairman and former AT&T chairman & CEO, discusses the issues around drug pricing and pharmaceutical companies.

  • Are cures bad for business?

    Discussing the potential downside to pharmaceutical companies developing cures with Dr. Peter Bach, Memorial Sloan Kettering Center for Health Policy, and Brian Skorney, Baird biotechnology analyst. CNBC's Meg Tirrell also weighs in.

  • Gilead's catch-22 on Hep C cure

    CNBC's Meg Tirrell reports on Gilead's new drug that cures Hepatitis C.

  • FRANKFURT, Feb 8- Bayer's best-selling blood-thinning drug Xarelto has also proved effective in preventing heart attacks and strokes in patients suffering from certain types of artery disease, the company said on Wednesday. The company, which is buying seeds maker Monsanto, raised its annual peak sales potential estimate for the drug last year to more than 5...

  • Feb 8- U.S. biopharmaceutical company Tesaro Inc is discussing its options with investment banks after receiving acquisition interest from several drugmakers, according to people familiar with the matter. Tesaro shares rose as much as 17 percent on the news and were up 11 percent at $180.50 in late morning trading in New York on Wednesday, giving the company a...

  • Feb 8- U.S. biopharmaceutical company Tesaro Inc is discussing its options with investment banks after receiving acquisition interest from several drug makers, according to people familiar with the matter. Tesaro is not actively exploring a sale, the people said this week, noting that there is a significant gap over the company's valuation between Tesaro and...

  • The company forecast 2017 hepatitis C drug sales of $7.5 billion- $9 billion, much lower than the $12 billion Wall Street analysts had expected, due to fewer patients starting on treatments and increased competition. Gilead's hepatitis C drugs Sovaldi and Harvoni revolutionized treatment of the serious liver disease, helping triple the company's sales to...

  • The company forecast 2017 hepatitis C drug sales of $7.5 billion to $9 billion, much lower than the $12 billion Wall Street had expected. "The 2017 guidance was $4- $5 billion lower than buyside expectations," said RBC Capital Markets analyst Michael Yee, adding that the sales outlook implies 2017 earnings for Gilead of $6.60- $9.00 per share, which is well below the...

  • The company said it expects 2017 hepatitis C drug sales of $7.5 billion to $9 billion, much lower than the $12 billion Wall Street analysts had expected, as compiled by Evercore ISI. "The 2017 guidance was $4- $5 billion lower than buyside expectations," said RBC Capital Markets analyst Michael Yee, adding that the sales outlook suggests 2017 earnings for Gilead of...

  • Feb 7- The U.S. Food and Drug Administration has approved Amgen Inc's treatment for secondary hyperparathyroidism in adult patients with chronic kidney disease undergoing dialysis, the U.S. biotech company said on Tuesday. The drug, etelcalcetide, will be sold under the brand name Parsabiv, Amgen said, adding that it is the first new therapy approved for the...

  • The company said it expects 2017 hepatitis C drug sales of $7.5 billion to $9 billion- much lower than the $12 billion Wall Street analysts had expected, as compiled by Evercore ISI. "The 2017 guidance was $4- $5 billion lower than buyside expectations and implied EPS 20-30 percent lower than consensus," said RBC Capital Markets analyst Michael Yee.

  • Following approval from the Food and Drug Administration, Phase I clinical trials will start in the first half of this year, the company said on Monday. Its first such "off-the-shelf" cell therapy UCART19, which is being developed with Servier and Pfizer, is now being tested in Phase I trials in Britain for acute lymphoblastic leukaemia and chronic lymphocytic...

  • Feb 6- Mylan NV has agreed to pay $96.5 million to settle claims by drug purchasers that it delayed launching a generic version of Cephalon Inc's narcolepsy drug Provigil in exchange for payment from Cephalon. The settlement was disclosed in a filing by the drug purchasers in Pennsylvania federal court on Friday, and must still be approved by the court.

  • Feb 6- Mylan NV has agreed to pay $96.5 million to settle claims by drug purchasers that it delayed launching a generic version of Cephalon Inc's narcolepsy drug Provigil in exchange for payment from Cephalon. The settlement was disclosed in a filing by the drug purchasers in Pennsylvania federal court on Friday, and must still be approved by the court.

  • Feb 2- Amgen Inc on Thursday posted a higher-than-expected fourth-quarter profit, helped by a jump in sales of its Enbrel rheumatoid arthritis drug, but it issued a 2017 sales and earnings forecast range below current Wall Street estimates. For 2017, Amgen forecast adjusted earnings of $11.80 to $12.60 per share, with a midpoint below Wall Street estimates of...

  • Feb 2- Amgen Inc on Thursday posted a higher-than-expected fourth-quarter profit, helped by a jump in sales of its Enbrel rheumatoid arthritis drug, but it issued a 2017 sales and earnings forecast range below current Wall Street estimates. For 2017, Amgen forecast adjusted earnings of $11.80 to $12.60 per share, with a midpoint below Wall Street estimates of...

  • Feb 2- Amgen Inc on Thursday posted a higher-than-expected fourth-quarter profit, helped by a jump in sales of its Enbrel rheumatoid arthritis drug, but it issued a 2017 sales and earnings forecast range below current Wall Street estimates. The world's largest biotechnology company said net profit in the latest quarter rose to $1.94 billion, or $2.59 per share,...

  • Feb 2- The U.S. Food and Drug Administration on Thursday expanded the use of Bristol-Myers Squibb Co's Opdivo to include treatment of urothelial carcinoma, the most common type of bladder cancer. Investors were disappointed last month when Bristol-Myers said it would not seek accelerated FDA approval for a combination of Opdivo and another immunotherapy,...